(19)
(11) EP 2 729 464 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
17.06.2015 Bulletin 2015/25

(45) Mention of the grant of the patent:
29.04.2015 Bulletin 2015/18

(21) Application number: 12731448.2

(22) Date of filing: 03.07.2012
(51) International Patent Classification (IPC): 
C07D 417/12(2006.01)
(86) International application number:
PCT/EP2012/062867
(87) International publication number:
WO 2013/004676 (10.01.2013 Gazette 2013/02)

(54)

CYCLOPROPYL-FUSED-1,3-THIAZEPINES AS BACE 1 AND/OR BACE 2 INHIBITORS

CYCLOPROPYL-KONDENSIERTE-1,3-THIAZEPINE ALS BACE 1- UND/ODER BACE-2-HEMMER

1,3-THIAZÉPINES À CYCLOPROPYLE FUSIONNÉ EN TANT QU'INHIBITEURS DE BACE 1 ET/OU DE BACE 2

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 06.07.2011 EP 11172784

(43) Date of publication of application:
14.05.2014 Bulletin 2014/20

(73) Proprietors:
  • F. Hoffmann-La Roche AG
    4070 Basel (CH)
  • Siena Biotech S.p.a.
    53100 Siena (IT)

(72) Inventor:
  • WOLTERING, Thomas
    79104 Freiburg (DE)

(74) Representative: Müller-Afraz, Simona 
F. Hoffmann-La Roche AG CLP - Patent Department Grenzacherstrasse 124
4070 Basel
4070 Basel (CH)


(56) References cited: : 
WO-A1-2011/005738
 WO-A1-2011/029803
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).